For semi‐quantitative analysis, the SUVmax was measured for the most clinically suspect prostatic lesion of each patient and was normalised for body weight. SUVmax was chosen because it does not require exact tumour borders as compared to SUVmean [22 (link)] and therefore is clinically most used. Suspect lesions were delineated according to the available clinical reports describing the dominant intraprostatic lesion. SUVmax was measured according to the E‐PSMA criteria and was compliant with EARL standards [14 (link), 15 (link)]. Volumes‐of‐interest (VOIs) were manually drawn at least 1.5 cm in diameter over the index lesion, carefully omitting physiological activity from the urethra or bladder. If no PSMA expression suspect for PCa was detected by the nuclear medicine physician, a VOI was drawn over the prostate location corresponding with a suspect lesion on multiparametric MRI (mpMRI), when available. Available clinical software of the Intellispace Portal (Philips®, the Netherlands/USA) and Osirix MD (Pixmeo SARL, Switzerland) were used to calculate the SUVmax. To cross‐validate both measuring software programs, identical scans from four patients were analysed with both programs, with 100% agreement.